- Home
- LSF vs EQ Comparison
LSF vs EQ Comparison
Compare LSF & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- EQ
- Stock Information
- Founded
- LSF 2015
- EQ 2017
- Country
- LSF United States
- EQ United States
- Employees
- LSF N/A
- EQ N/A
- Industry
- LSF Packaged Foods
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- EQ Health Care
- Exchange
- LSF Nasdaq
- EQ Nasdaq
- Market Cap
- LSF 62.0M
- EQ 57.8M
- IPO Year
- LSF 2020
- EQ 2018
- Fundamental
- Price
- LSF $2.74
- EQ $1.06
- Analyst Decision
- LSF Strong Buy
- EQ Hold
- Analyst Count
- LSF 1
- EQ 1
- Target Price
- LSF $12.00
- EQ $1.00
- AVG Volume (30 Days)
- LSF 90.1K
- EQ 407.3K
- Earning Date
- LSF 11-10-2025
- EQ 11-13-2025
- Dividend Yield
- LSF N/A
- EQ N/A
- EPS Growth
- LSF N/A
- EQ N/A
- EPS
- LSF N/A
- EQ N/A
- Revenue
- LSF $48,146,862.00
- EQ $4,392,000.00
- Revenue This Year
- LSF $21.88
- EQ N/A
- Revenue Next Year
- LSF $20.86
- EQ N/A
- P/E Ratio
- LSF N/A
- EQ N/A
- Revenue Growth
- LSF 17.73
- EQ N/A
- 52 Week Low
- LSF $2.52
- EQ $0.27
- 52 Week High
- LSF $10.90
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- LSF 18.84
- EQ 41.42
- Support Level
- LSF $2.52
- EQ $1.31
- Resistance Level
- LSF $4.30
- EQ $1.58
- Average True Range (ATR)
- LSF 0.32
- EQ 0.14
- MACD
- LSF -0.19
- EQ -0.04
- Stochastic Oscillator
- LSF 8.07
- EQ 36.27
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.